The Role of Chinese Biotechs in the BD Process for Immuno-Oncology

Andrew Baum, MD, joined Citi in September 2011, as the Global Head of Healthcare Research. He benefits from a deep strategic insight of the global healthcare value chain, as well as broad network of contacts throughout the industry. In 2004, Dr Baum was one of the earliest commentators to highlight to investors the deep structural deficiencies of the historic operating structure and the need to evolve towards a radically different model.Dr Baum is widely sought after to share his insights with the most senior levels of management within the healthcare industry. He regularly lectures for a number of prestigious organisations including The Institute of Comparative Law, The World Vaccine Congress as well as occasional presentations to some of the leading management consultancies.Before joining the firm, Dr Baum was at Morgan Stanley 14-years, where he was the top ranked European Pharmaceutical Analyst in the Extel Poll for six years. Dr Baum and his team consistently ranked in the top three teams in external EU and Global investor polls (Institutional Investor, Greenwich and Reuters). Before this, Dr Baum was a UK pharmaceutical and biotechnology analyst at Salomon Brothers. From 1994 to 1996, he was a practicing physician at the Royal National Orthopaedic Radcliffe Hospital in Oxford (the medical centre of Oxford University) where he completed his residency. Dr Baum is a member of the American Heart Association, American Society of Oncology and the DIA. He is also a Fellow of the Royal Society of Medicine. Dr Baum holds an MA in Physiological Sciences and an MD from Oxford University.

Meeta Chatterjee, PhD has served as the Senior Vice President of Global Business Development since March, 2019. She was previously Head of Strategy, Transactions, and Operations within the Business Development and Licensing (BD&L) group at Merck Research Labs. Dr Chatterjee oversaw discovery and late-stage transactions worldwide, as well as early-stage transactions in key geographies. She also was responsible for Merck’s BD&L governance, oversight, and control as well as out-licensing efforts.Dr Chatterjee has over 30 years of broad strategic and operational experience in pharmaceutical research and development, mergers and acquisition evaluation, in-licensing, and externalization activities. Over the course of her extensive career, she has led/contributed to >150 transactions/collaborations with a cumulative financial value of ~$1 billion USD. She has led research efforts in the areas of hypertension, atherosclerosis, and obesity, and was an integral contributor to the discovery of ZETIA and ZONTIVITY.Dr Chatterjee received her undergraduate education at St. Xavier’s University in Ahmedabad, India, and Rutgers University (BA, Hons Physics), New Jersey, USA. She received her Doctor of Philosophy in Physiology from Rutgers University and completed a postdoctoral fellowship in the Department of Physiology at the University of Virginia, School of Medicine, Virginia, USA. Dr Chatterjee is also active in industry and licensing focused organizations.

Angus Grant, PhD, joined BeiGene in June 2020 as Chief Business Executive, bringing in more than 25 years of experience across multiple key functions in the biotech industry, including business development, alliance management, research and development, and regulatory affairs . In this role, Dr Grant oversees business development and alliance management, and help drive external innovation and investment in other companies to guide BeiGene’s global growth strategy. Prior to joining BeiGene, Dr Grant was the CEO of the Dementia Discovery Fund (DDF), a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Before that, Dr Grant spent 12 years at Celgene (now a Bristol Myers Squibb company) serving various executive roles, including Corporate Vice President of Business Development and Vice President, Regulatory Affairs. Earlier in his career, Dr Grant worked in business development and regulatory roles at Novartis, Merck KGaA, Rhone Poulanc-Rohrer, SmithKline Beecham, and the US Food and Drug Administration’s Center for Biologics. He currently serves as the Chairman of the Board for Toronto Innovation and Acceleration Partners. Dr Grant received a bachelor’s degree from the University of Richmond and a PhD in Anatomy and Immunology from the Medical College of Virginia, and completed his postdoctoral training at the National Cancer Institute.

Weimin Tang, PhD is currently EVP of I-MAB Biopharma, a clinical stage biotech company focus on Immunology and Oncology. He served as Interim CEO/Head of US Business Development, Jiangsu Hengrui Medicine previously and build Hengrui global business development team and clinical operation in Princeton, NJ. He was trained as cancer biologist with PhD in Biochemistry at Rutgers University. He has accumulated more than 20 years of research and business management experiences with global pharmaceutical companies and Biotechs such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, Crown Biosciences, Hengrui Medicine and I-MAB Biopharma. Through his industry career, he expanded his function from basic biology to high throughput screening, DMPK and business management. Dr. Tang received his Bachelor’s Degree from Zhejiang University, Master Degree from Chinese Academy of Sciences.